Patents by Inventor Mark Mattencci

Mark Mattencci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
    Patent number: 7057027
    Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.
    Type: Grant
    Filed: December 8, 2003
    Date of Patent: June 6, 2006
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brian Froehler, Rick Wagner, Mark Mattencci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
  • Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
    Publication number: 20040220395
    Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.
    Type: Application
    Filed: December 8, 2003
    Publication date: November 4, 2004
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Brian Froehler, Rick Wagner, Mark Mattencci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
  • Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
    Patent number: 6380368
    Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.
    Type: Grant
    Filed: February 12, 1996
    Date of Patent: April 30, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brian Froehler, Rick Wagner, Mark Mattencci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo